Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.
Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.
使用 FOLFOXIRI 加贝伐珠单抗治疗的仅肝转移性结直肠癌患者从不可切除的肝转移转变为可切除的肝转移。
批准号：
388409
负责人：
Ahmed Shahid
金额：
$7.29万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-09-01 至 2021-09-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Colorectal cancer is the second leading cause of cancer deaths in Canada. Patients with metastatic colorectal cancer generally have a life expectancy of 24-30 months, however, a small number of patients with metastatic cancer that is confined to the liver
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
